mRNA vaccines like Pfizer and Moderna fare better against COVID-19 variants of concern

moderna
Credit: Unsplash/CC0 Public Domain

A comparison of four COVID-19 vaccinations shows that messenger RNA (mRNA) vaccines from Pfizer-BioNTech and Moderna perform better against the World Health Organization's variants of concern (VOCs) than viral vector vaccines from AstraZeneca and J&J/Janssen. Although they all effectively prevent severe disease by VOCs, the research, published May 17th in the open access journal PLoS Medicine, suggests that people receiving a viral vector vaccine are more vulnerable to infection by new variants.

By March 2022, COVID-19 had caused over 450 million confirmed infections and six million reported deaths. The first vaccines approved in the US and Europe that protect against serious infection are Pfizer-BioNTech and Moderna, which deliver , known as mRNA, to the bodies' cells, whereas Oxford/AstraZeneca and J&J/Janssen are viral vector vaccines that use a modified version of a different virus—a vector—to deliver instructions to our cells. Three vaccines are delivered as two separate injections a few weeks apart, and J&J/Janssen as a single dose.

Marit J. van Gils at the University of Amsterdam, Netherlands, and colleagues, took from 165 health care workers, three and four weeks after first and second vaccination respectively, and for J&J/Janssen at four to five and eight weeks after vaccination. Samples were collected before, and four weeks after a Pfizer-BioNTech booster.

Four weeks after the initial two doses, to the original SARS-CoV-2 viral strain were highest in recipients of Moderna, followed closely by Pfizer-BioNTech, and were substantially lower in those who received viral vector vaccines. Tested against the VOCs—alpha, beta, gamma, delta and omicron—neutralizing antibodies were higher in the mRNA vaccine recipients compared to those who had viral vector vaccines. The ability to neutralize VOCs was reduced in all vaccine groups, with the greatest reduction against omicron. The Pfizer-BioNTech booster increased antibody responses in all groups with substantial improvement against VOCs, including omicron.

The researchers caution that their AstraZeneca group was significantly older, because of safety concerns for the vaccine in younger age groups. As immune responses tend to weaken with age, this could affect the results. This group was also smaller because the Dutch government halted use for a period.

"Four COVID-19 vaccines induce substantially different antibody responses," concluded van Gils.


Explore further

Pfizer booster more than 50% protective against omicron

More information: Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study, PLoS Medicine (2022). DOI: 10.1371/journal.pmed.1003991
Journal information: PLoS Medicine

Citation: mRNA vaccines like Pfizer and Moderna fare better against COVID-19 variants of concern (2022, May 17) retrieved 1 July 2022 from https://medicalxpress.com/news/2022-05-mrna-vaccines-pfizer-moderna-fare.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
138 shares

Feedback to editors